5.43
price up icon6.26%   0.32
after-market 시간 외 거래: 5.30 -0.13 -2.39%
loading
전일 마감가:
$5.11
열려 있는:
$5.13
하루 거래량:
1.39M
Relative Volume:
1.06
시가총액:
$749.25M
수익:
$62.04M
순이익/손실:
$-533.34M
주가수익비율:
-1.3852
EPS:
-3.92
순현금흐름:
$-473.07M
1주 성능:
+4.62%
1개월 성능:
+7.10%
6개월 성능:
-25.31%
1년 성능:
-38.64%
1일 변동 폭
Value
$5.015
$5.44
1주일 범위
Value
$4.91
$5.44
52주 변동 폭
Value
$4.32
$14.45

비르 바이오테크 Stock (VIR) Company Profile

Name
명칭
Vir Biotechnology Inc
Name
전화
415-906-4324
Name
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Name
직원
408
Name
트위터
@Vir_Biotech
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
VIR's Discussions on Twitter

VIR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VIR
Vir Biotechnology Inc
5.43 749.25M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

비르 바이오테크 Stock (VIR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-01-29 다운그레이드 JP Morgan Overweight → Neutral
2023-09-08 다운그레이드 BofA Securities Buy → Neutral
2023-03-06 업그레이드 JP Morgan Neutral → Overweight
2023-02-21 업그레이드 Goldman Neutral → Buy
2023-01-27 업그레이드 Morgan Stanley Underweight → Equal-Weight
2022-09-14 개시 SVB Leerink Outperform
2022-09-09 개시 Morgan Stanley Underweight
2022-03-03 업그레이드 Robert W. Baird Underperform → Neutral
2021-12-21 다운그레이드 Robert W. Baird Neutral → Underperform
2021-10-25 업그레이드 JP Morgan Underweight → Neutral
2021-09-22 다운그레이드 Goldman Buy → Neutral
2021-06-04 재개 Robert W. Baird Neutral
2021-01-27 다운그레이드 JP Morgan Neutral → Underweight
2021-01-20 재확인 H.C. Wainwright Buy
2020-10-05 개시 BofA Securities Buy
2020-09-14 업그레이드 Goldman Neutral → Buy
2020-09-11 업그레이드 JP Morgan Underweight → Neutral
2020-08-20 개시 Needham Buy
2020-03-19 다운그레이드 JP Morgan Neutral → Underweight
2020-03-13 다운그레이드 Goldman Buy → Neutral
2020-02-27 다운그레이드 Robert W. Baird Neutral → Underperform
2020-02-04 다운그레이드 JP Morgan Overweight → Neutral
2019-11-14 개시 Robert W. Baird Neutral
2019-11-05 개시 Barclays Overweight
2019-11-05 개시 Cowen Outperform
2019-11-05 개시 Goldman Buy
2019-11-05 개시 JP Morgan Overweight
모두보기

비르 바이오테크 주식(VIR)의 최신 뉴스

pulisher
Jun 17, 2025

Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 10, 2025

Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener

Jun 10, 2025
pulisher
Jun 05, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 03, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia

Jun 03, 2025
pulisher
Jun 02, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
May 29, 2025

Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks

May 29, 2025
pulisher
May 29, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace

May 29, 2025
pulisher
May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com

May 27, 2025
pulisher
May 22, 2025

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

May 22, 2025
pulisher
May 22, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace

May 21, 2025
pulisher
May 20, 2025

Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

May 20, 2025
pulisher
May 15, 2025

How To Trade (VIR) - news.stocktradersdaily.com

May 15, 2025
pulisher
May 15, 2025

Vir announces 24-week post-end of treatment data for Hep B therapy - MSN

May 15, 2025
pulisher
May 14, 2025

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN

May 14, 2025
pulisher
May 12, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace

May 12, 2025
pulisher
May 12, 2025

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

May 12, 2025
pulisher
May 12, 2025

Vir Biotechnology Announces Results of Its Potential Hepatitis B Cure Combination Therapy - ContagionLive

May 12, 2025
pulisher
May 11, 2025

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

May 11, 2025
pulisher
May 10, 2025

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Trea - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Tr - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks

May 08, 2025

비르 바이오테크 (VIR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):